Genomically driven breast cancer trial: Ready to play?
This article was originally published in Scrip
Just as an FDA-convened 21 October workshop was winding down after a day full of rapid-fire presentations and thought-provoking discussions about how to go about putting together a global collaboration for an international genomically driven master protocol trial to simultaneously test several targeted breast cancer drugs in multiple treatment arms, a new debate erupted about how to ensure the meeting does not simply lead to more talk and no action.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.